Clinical Development Pipeline Featuring CBP501 and CBS9106
First written in FY2016. 14 of 35 entries say "Advanced", first in FY2017. Latest entry: 2026-10-14.
0 other companies' latest entry also says "Reframed".
- FY2026SoftenedAnnual report
「The pharmaceutical candidates currently in clinical development are at the preparation stage for the next clinical trial for CBP501, which targets pancreatic cancer, while CBS9106 has completed its Phase 1 trial and is at the planning stage for the next clinical trial.」
The disclosure describes preparations for the next phase following completion of the Phase 2 trial of CBP501 and the completion of Phase 1 and planning for the next phase of CBS9106, but does not include the specific reference in the immediately preceding half-year filing to preparations for a Phase 3 trial of CBP501. - FY2026-H1AdvancedAnnual report
「The clinical-stage drug candidate compounds currently under development are at the stage of preparing a Phase 3 clinical trial for CBP501 in pancreatic cancer, while CBS9106 has completed its Phase 1 clinical trial and is at the stage of considering its future development strategy.」
For CBP501, the description changed from preparations for the next clinical trial phase to explicitly stating that it is at the preparation stage for a Phase 3 clinical trial for pancreatic cancer. Following completion of its Phase 1 trial, CBS9106 is at the stage of considering its future development policy. - FY2025ReframedAnnual report
「Regarding the second drug candidate, CBS9106, the US-based partner Stemline completed a Phase 1 clinical trial primarily evaluating safety in patients with advanced solid tumours, and all rights were returned to the company in June 2025. Going forward, the company plans to consider its development policy, including plans for the next clinical trial phase, taking into account the results of additional basic research and the company's financial position.」
While CBP501 is at the stage of completing its Phase 2 trial and preparing for the next phase, all rights to CBS9106 were returned by Stemline following completion of its Phase 1 trial. Its status changed from planning for the next phase by the licensee to reconsideration of its development policy by the company. - FY2025-H1RestatedAnnual report
「The company's drug candidates currently under development are at the preparation stage for a next-phase clinical trial of CBP501 for pancreatic cancer, and CBS9106 has completed its Phase 1 clinical trial and is at the stage where the licensee is planning the next-phase clinical trial.」
The company reconfirmed the status of its clinical development pipeline comprising preparations for CBP501's next clinical trial phase and completion of CBS9106's Phase 1 trial and planning for the next phase by its licensee. - FY2024AdvancedAnnual report
「The company has successfully completed the Phase 2 clinical trial for CBP501, which evaluated efficacy, safety and dosing, and is preparing for the next clinical trial phase. Stemline has completed the Phase 1 clinical trial for CBS9106 (felezonexor), and planning for the next clinical trial phase is under way.」
In the clinical development pipeline, CBP501 progressed to the stage of completing its Phase 2 trial and preparing for the next phase, while CBS9106 progressed to the stage of completing its Phase 1 trial and planning for the next phase. - FY2024-Q3AdvancedAnnual report
「In response, the company obtained regulatory approval in the US to begin the Phase 2b trial, the next clinical trial phase, and is proceeding with some preparations for its start. In Europe, it is currently carrying out regulatory filings and preparations to begin a Phase 3 trial, with the aim of obtaining approval.」
In the clinical development pipeline, CBP501 progressed to the preparation stage following approval to begin the Phase 2b trial in the US, and to the regulatory filing and preparation stage for starting a Phase 3 trial in Europe. Following completion of its Phase 1 trial, CBS9106 is at the stage where its licensee is planning the next trial phase. - FY2024-Q1RestatedAnnual report
「The drug candidates currently under development are at the preparation stage for the next clinical trial in pancreatic cancer for CBP501, while CBS9106 has completed its Phase 1 clinical trial and is at the planning stage for the next clinical trial.」
The company reconfirmed the status of its clinical development pipeline comprising preparations for CBP501's next clinical trial phase and completion of CBS9106's Phase 1 trial and planning for the next phase. - FY2023SoftenedAnnual report
「The drug candidates currently under development are at the stage of a Phase 2 clinical trial for pancreatic cancer for CBP501, while CBS9106 has completed its Phase 1 clinical trial and is at the planning stage for the next clinical trial phase.」
For CBP501, the description is limited to the Phase 2 trial and preparations for the next phase; the achievement of the primary endpoint and preparations for a Phase 3 trial explicitly stated in the immediately preceding quarter's filing are not mentioned. - FY2023-Q3RestatedAnnual report
「The drug candidates currently under development are CBP501, for which the primary endpoint was achieved in the Phase 2 clinical trial and early termination was decided, with preparations under way to begin the Phase 3 clinical trial, and CBS9106, which has completed its Phase 1 clinical trial.」
The company reconfirmed the clinical development pipeline comprising completion of the CBP501 Phase 2 trial and preparations for a Phase 3 trial, and completion of the CBS9106 Phase 1 trial. - FY2023-Q2AdvancedAnnual report
「The trial achieved its primary endpoint in the three-drug combination arm including CBP501, and the Company decided to end the trial early after the first stage of its two-stage design. Preparations are currently under way to begin a Phase 3 clinical trial.」
In the clinical development pipeline, CBP501 achieved its primary endpoint in the first stage of its Phase 2 trial and, following its early termination, progressed to preparations to begin a Phase 3 trial. CBS9106 remains at the stage following completion of its Phase 1 trial. - FY2023-Q1AdvancedAnnual report
「Under US FDA regulation, the Company is conducting a Phase 2 clinical trial combining CBP501 with an immune checkpoint inhibitor antibody for third-line treatment of pancreatic cancer. The trial has completed subject enrollment in the first stage of a two-stage design, and dosing and observation are continuing.」
In the clinical development pipeline, CBP501 progressed to dosing and observation after completion of subject enrolment in the first stage of its Phase 2 trial. CBS9106 remains at the stage following completion of its Phase 1 trial. - FY2022RestatedAnnual report
「The drug candidates currently under development are at the stage of a Phase 2 clinical trial for pancreatic cancer for CBP501, while CBS9106 has completed its Phase 1 clinical trial and is at the planning stage for the next clinical trial phase.」
The company reconfirmed the status of its clinical development pipeline, comprising the CBP501 Phase 2 trial and CBS9106's completed Phase 1 trial and planning for the next phase. - FY2022-Q3AdvancedAnnual report
「The drug candidate compounds currently under development are at the early stage of the Phase 2 clinical trial for CBP501, while CBS9106 has completed its Phase 1 clinical trial.」
In the clinical development pipeline, CBP501 progressed into the early stages of its Phase 2 trial, while CBS9106 reached the stage following completion of its Phase 1 trial. - FY2022-Q2RestatedAnnual report
「The drug candidates currently under development are in the early stages of the Phase 2 clinical trial for CBP501 and the latter stages of the Phase 1 clinical trial for CBS9106.」
The company reconfirmed the status of its clinical development pipeline comprising multiple drug candidates, with CBP501 in the early stages of its Phase 2 trial and CBS9106 in the latter stages of its Phase 1 trial. - FY2022-Q1AdvancedAnnual report
「The clinical trial is currently in its final stages, having completed dosing in the expansion phase, the second part of the trial, for pancreatic and colorectal cancer, and is awaiting receipt of the final report. The subsequent Phase 2 clinical trial is under way.」
In the clinical development pipeline, CBP501 progressed from the final stages of the Phase 1b expansion phase to the start of the Phase 2 clinical trial. CBS9106 was reported to be in the latter stages of its Phase 1 clinical trial. - FY2021AdvancedAnnual report
「The clinical trial is currently in its final stages, having completed dosing in the expansion phase, the second part of the trial, for pancreatic and colorectal cancer. The application to initiate the Phase 2 clinical trial has already been approved, and preparations are under way to begin dosing.」
CBP501 completed dosing in the Phase 1b expansion phase and, following approval of the application to begin the Phase 2 clinical trial, progressed to preparations for dosing. CBS9106 remains at the Phase 1 clinical trial stage. - FY2021-Q3RestatedAnnual report
「The drug candidates currently under development are in the latter stages of the Phase 1b trial for CBP501 and at the Phase 1 clinical trial stage for CBS9106.」
The company continues its clinical development pipeline comprising CBP501 in the latter stages of its Phase 1b trial and CBS9106 in its Phase 1 clinical trial. - FY2021-Q2AdvancedAnnual report
「The clinical trial is currently in its final stages, having completed dosing in the expansion phase, the second part of the trial, for pancreatic and colorectal cancer, and preparations are under way for the next clinical trial.」
CBP501 completed dosing in the Phase 1b expansion phase and progressed from the latter stages of that trial to preparations for the next clinical trial phase. CBS9106 remains at the Phase 1 clinical trial stage. - FY2021-Q1AdvancedAnnual report
「The drug candidates currently under development are in the latter stages of the Phase 1b trial for CBP501 and at the Phase 1 clinical trial stage for CBS9106.」
CBP501 has reached the latter stages of its Phase 1b trial, with concrete progress including completion of enrolment in the expansion phase. CBS9106 remains at the Phase 1 clinical trial stage. - FY2020RestatedAnnual report
「The drug candidates currently under development are at the Phase 1b trial stage for CBP501, following completion of its Phase 2 clinical trial, and at the Phase 1 clinical trial stage for CBS9106.」
The company continues its clinical development pipeline comprising the CBP501 Phase 1b trial and the CBS9106 Phase 1 trial. - FY2020-Q3RestatedAnnual report
「The drug candidate compounds currently under development are at the Phase 1b clinical trial stage for CBP501 and the Phase 1 clinical trial stage for CBS9106.」
The company continues its clinical development pipeline comprising the CBP501 Phase 1b trial and the CBS9106 Phase 1 trial. - FY2020-Q2RestatedAnnual report
「The drug candidate compounds currently under development are at the Phase 1b clinical trial stage for CBP501 and the Phase 1 clinical trial stage for CBS9106.」
The company continues its clinical development pipeline comprising the CBP501 Phase 1b trial and the CBS9106 Phase 1 trial. - FY2020-Q1RestatedAnnual report
「The drug candidate compounds currently under development are at the stage of conducting a Phase 1b clinical trial for CBP501 based on new findings following completion of the Phase 2 clinical trial, and at the Phase 1 clinical trial stage for CBS9106.」
The company continues its clinical development pipeline comprising the CBP501 Phase 1b trial and the CBS9106 Phase 1 trial. - FY2019-Q3RestatedAnnual report
「The drug candidate compounds currently under development are at the stage of conducting a Phase 1b clinical trial for CBP501 based on new findings following completion of the Phase 2 clinical trial, and at the Phase 1 clinical trial stage for CBS9106.」
The company continues its clinical development pipeline comprising the CBP501 Phase 1b trial and the CBS9106 Phase 1 trial. - FY2019-Q2AdvancedAnnual report
「During the cumulative first half of the fiscal year, the company completed the dose-escalation phase, the first part of the Phase 1b trial, and, after reviewing the results, began the expansion phase, the second part, for pancreatic cancer and colorectal cancer.」
CBP501's development pipeline progressed from completion of the dose-escalation phase of the Phase 1b trial to the start of the expansion phase for pancreatic and colorectal cancer. - FY2019-Q1RestatedAnnual report
「The drug candidate compounds currently under development are at the stage of conducting a Phase 1b clinical trial for CBP501 based on new findings following completion of the Phase 2 clinical trial, and at the Phase 1 clinical trial stage for CBS9106.」
The company continues its clinical development pipeline comprising the CBP501 Phase 1b trial and the CBS9106 Phase 1 trial. - FY2018-Q3RestatedAnnual report
「The drug candidate compounds currently under development are at the stage of conducting a Phase 1b clinical trial for CBP501 based on new findings following completion of the Phase 2 clinical trial, and at the Phase 1 clinical trial stage for CBS9106.」
The company continues its clinical development pipeline comprising the CBP501 Phase 1b trial and the CBS9106 Phase 1 trial. - FY2018-Q2RestatedAnnual report
「The drug candidate compounds currently under development are at the stage of conducting a Phase 1b clinical trial for CBP501 based on new findings following completion of the Phase 2 clinical trial, and at the Phase 1 clinical trial stage for CBS9106.」
The company continues its clinical development pipeline comprising the CBP501 Phase 1b trial and the CBS9106 Phase 1 trial. - FY2018-Q1AdvancedAnnual report
「The Company reviewed its previous clinical development plan, which had assumed that the next clinical trial for CBP501 would be a Phase 2b trial, and, based on newly obtained findings, initiated a clinical trial combining CBP501 with an immune checkpoint inhibitor antibody, namely a Phase 1b trial.」
The company stated that it had begun the Phase 1b trial in the CBP501 development pipeline. However, enrolment of subjects had not begun by the end of the quarter. - FY2017AdvancedAnnual report
「April 2017: Obtained FDA IND approval to initiate a Phase 1b clinical trial combining CBP501, cisplatin and an immune checkpoint inhibitor antibody.」
The company obtained the FDA's IND approval required to begin the next clinical trial for CBP501. - FY2017-Q3Approval to begin the Phase 1b trial not obtainedAnnual report
「Approval to begin the trial had not been obtained by the end of the third quarter, and only the amount incurred for preparations was recorded as an expense.」
Preparations to begin the Phase 1b trial for the next stage of CBP501 were under way, but approval to begin it had not been obtained by the end of the third quarter. - FY2017-Q1ReframedAnnual report
「During the cumulative first-quarter period, the Company reviewed its clinical development plan, which had assumed that the next clinical trial for CBP501 would be a Phase 2b trial, and decided to prepare with the aim of newly initiating a Phase 1b trial.」
For the development pipeline comprising CBP501 and CBS9106, CBP501's next clinical stage changed from an assumed Phase 2b trial to preparations to begin a Phase 1b trial. - FY2016First statedAnnual report
「The company is currently building its development pipeline around CBP501 and CBS9106 and advancing R&D based on prioritisation and management focused on commercialisation.」
The development status of the 2 products is that CBP501 has completed its Phase 2 trial, while CBS9106 is undergoing a Phase 1 trial.